Revolutionary 4-in-1 Weight Loss Drug Promises to Outperform Mounjaro and Ozempic – But When Will It Actually Arrive?

Ever wonder if technology might just sneak up and turn your weight loss journey into a walk in the park? Well, buckle up, because scientists at Tufts University are cooking up something wild—a new weight loss drug that’s basically the lovechild of Mounjaro and Ozempic. Imagine a “4-in-1” powerhouse that targets four hormone receptors and can slash your weight by up to 30 percent, putting it on the same leaderboard as bariatric surgery—yet without the scalpels and hospital stays. With weight loss injections already helping over 1.5 million Brits shed pounds, this could be the ultimate game changer for those dodging invasive surgeries. Sure, it’s still in the lab, and the road to your local pharmacy might be several years long, but this drug’s potential to reshape how we tackle obesity is downright electrifying. Ready to dive deeper into the science and future of this quadruple-action marvel? LEARN MORE

A new weight loss drug that ‘combines Mounjaro and Ozempic effects’ is being developed by scientists.

Weight loss jabs have become increasingly popular in recent years, helping an estimated 1.5 million people in the UK shed the pounds.

Now, a team of researchers at Tufts University in Massachusetts are working on creating a ‘quadruple-action’ drug, which has been dubbed a ‘4-in1’.

The drug would target four hormone receptors and could result in weight loss of up to 30 percent which puts it on par with bariatric surgery – this includes procedures such as gastric bypass, sleeve gastrectomy, and gastric banding.

It would essentially be a game changer for patients, as it would avoid invasive surgeries.

The new drug is said to ‘combine the effects of Mounjaro and Ozempic’ (Getty Stock Image)

How does it work?

Well, you might know that Wegovy and Ozempic (which is not prescribed for weight loss but for patients with type 2 diabetes) target the GLP-1 receptor, which helps communicate to your body that you’re full.

Mounjaro also targets the GIP receptor, while another drug, called Retatrutide targets glucagon, which increases your blood glucose but also raises energy use in your body and suppresses your appetite.

Now, a new drug would try and target a fourth receptor, known as peptide YY. This would essentially make the drug an alternative to bariatric surgery.

Study lead author Tristan Dinsmore said targeting peptide YY could also help burn off fat directly instead of doing it by suppressing appetite.

Explaining how this works, he said: “There is one more hormone we wanted to bring in to complete a weight control quartet. It’s called peptide YY. This molecule is also secreted by the gut after we eat a meal, and its job is to reduce appetite and slow the process of emptying food from the stomach, but via different mechanisms than either GLP-1 or GIP.

“It may also be involved in directly ‘burning off’ fat.”

The drug is said to target four hormone receptors (Getty Stock Image)

When will the new drug be released?

The new drug is yet to be trialled in human studies, which means it will likely be a number of years before it can actually be rolled out to the public.

Typically, this can last for several years before the drug is available.

In one study in The Lancet, the median development time from the first human study to authorisation was 7.3 years.

The drug is expected to take a number of years (Getty Stock Image)

The study explained: “However, there was considerable variability, with the fastest project taking only 8 months and the slowest extending to 223 months.

“The analysis revealed that vaccines and drugs against COVID-19 had the shortest development timelines, followed by interventions against Ebola virus disease and Hepatitis A-E. Interestingly, no significant differences in development times were observed between vaccines and drugs.”